AbbVie Inc. (0QCV.IL)
AbbVie Inc.
1 North Waukegan Road
North Chicago, IL 60064-6400
United States
847 932 7900
https://www.abbvie.com
Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 50,000
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Richard A. Gonzalez | Chairman & CEO | 6.95M | N/A | 1954 |
| Mr. Robert A. Michael | Pres & COO | 4M | N/A | 1970 |
| Mr. Scott T. Reents | Exec. VP & CFO | 2.97M | N/A | 1968 |
| Dr. Azita Saleki-Gerhardt Ph.D. | Exec. VP & COO | 2.58M | N/A | 1963 |
| Mr. Jeffrey Ryan Stewart | Exec. VP & Chief Commercial Officer | 2.98M | 2.78M | 1969 |
| Dr. Thomas J. Hudson M.D. | Sr. VP of R&D and Chief Scientific Officer | N/A | N/A | 1962 |
| Ms. Elizabeth Shea | Sr. VP of Investor Relations | N/A | N/A | N/A |
| Mr. Sanjay Narayan | VP, Chief Ethics & Compliance Officer | N/A | N/A | N/A |
| Ms. Tracie Haas | Sr. VP of Corp. Responsibility, Brand & Communications | N/A | N/A | N/A |
| Mr. Timothy J. Richmond | Exec. VP & Chief HR Officer | N/A | N/A | 1966 |
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Corporate governance
AbbVie Inc.’s ISS governance QualityScore as of 1 October 2023 is 9. The pillar scores are Audit: 9; Board: 7; Shareholder rights: 9; Compensation: 7.
